Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| VU-VICC-HEM-0750 | |||
| VU-VICC-070644 |
Not provided
Not provided
Not provided
The original PI on this study left VICC, thus study was closed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Studying blood or mouthwash samples in the laboratory from patients receiving melphalan for cancer may help doctors learn more about changes that occur in DNA, identify biomarkers related to cancer, and help predict how patients will respond to treatment.
PURPOSE: This clinical trial is studying common genetic mutations related to mucositis in patients with multiple myeloma receiving high-dose melphalan.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Blood or mouthwash samples are collected and DNA isolated from these specimens is analyzed for single nucleotide polymorphisms (SNPs) in LAT1 or other candidate genes. Public databases (i.e., dbSNP and HapMap) are reviewed to select representative SNPs for genotype analysis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Retrospective sample | People who have been diagnosed with multiple myeloma and have received high-dose melphalan. |
| |
| Prospective sample | People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| laboratory biomarker analysis | Other | Blood or cheek cells wil be collected. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Association between single nucleotide polymorphisms (SNPs) in genes that encode the melphalan transporters and development and/or severity of mucositis | 4 weeks | |
| Association between SNPs in genes that influence melphalan metabolism and development and/or severity of mucositis | 4 weeks |
Not provided
Not provided
DISEASE CHARACTERISTICS:
Diagnosis of multiple myeloma
Receiving treatment with high-dose melphalan for an autologous stem cell transplantation at any of these facilities:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
People who have been diagnosed with multiple myeloma and have received or will be receiving high-dose melphalan.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephen Brandt, MD | Vanderbilt-Ingram Cancer Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vanderbilt-Ingram Cancer Center at Franklin | Nashville | Tennessee | 37064 | United States | ||
| Veterans Affairs Medical Center - Nashville |
Not provided
Not provided
Not provided
Not provided
Blood sample or cheek cells will be collected.
| Nashville |
| Tennessee |
| 37212 |
| United States |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232-6838 | United States |
| ID | Term |
|---|---|
| D052016 | Mucositis |
| D009101 | Multiple Myeloma |
| D054219 | Neoplasms, Plasma Cell |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D020141 | Hemostatic Disorders |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D010265 | Paraproteinemias |
| D001796 | Blood Protein Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006474 | Hemorrhagic Disorders |
| D008232 | Lymphoproliferative Disorders |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided